Atrial natriuretic peptide: Old but new therapeutic in cardiovascular diseases

Tomoko Ichiki, John C Jr. Burnett

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

With the discovery of atrial natriuretic peptide (ANP), the heart as an endocrine organ was established. Basic science revealed that ANP, through the particulate guanylyl cyclase A receptor and cGMP, plays a fundamental role in cardiorenal biology. This work has led to the development of ANP as a therapeutic, especially in heart failure (HF). Human genomics has strengthened our understanding of ANP, revealing specific ANP gene variants that may be associated with biological dysfunction, but also may mediate protective properties, including in metabolic syndrome. Advances in understanding the processing and degradation of ANP molecular forms have resulted in therapeutic breakthroughs, especially inhibition of ANP degradation by neprilysin inhibitors. Although ANP is administered intravenously for acute HF, a novel therapeutic strategy is its chronic delivery by subcutaneous injection. An innovative therapeutic development is engineering to develop ANP-based peptides for chronic use. These interconnected topics of ANP biology and therapeutics will be reviewed in detail.

Original languageEnglish (US)
Pages (from-to)913-919
Number of pages7
JournalCirculation Journal
Volume81
Issue number7
DOIs
StatePublished - 2017

Fingerprint

Atrial Natriuretic Factor
Cardiovascular Diseases
Therapeutics
Heart Failure
Neprilysin
Subcutaneous Injections
Genomics
Peptides

Keywords

  • Atrial natriuretic peptide
  • Cardiorenal biology
  • cGMP

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Atrial natriuretic peptide : Old but new therapeutic in cardiovascular diseases. / Ichiki, Tomoko; Burnett, John C Jr.

In: Circulation Journal, Vol. 81, No. 7, 2017, p. 913-919.

Research output: Contribution to journalReview article

@article{4d4ba1958f7840f6b9412dc37ddb8c2b,
title = "Atrial natriuretic peptide: Old but new therapeutic in cardiovascular diseases",
abstract = "With the discovery of atrial natriuretic peptide (ANP), the heart as an endocrine organ was established. Basic science revealed that ANP, through the particulate guanylyl cyclase A receptor and cGMP, plays a fundamental role in cardiorenal biology. This work has led to the development of ANP as a therapeutic, especially in heart failure (HF). Human genomics has strengthened our understanding of ANP, revealing specific ANP gene variants that may be associated with biological dysfunction, but also may mediate protective properties, including in metabolic syndrome. Advances in understanding the processing and degradation of ANP molecular forms have resulted in therapeutic breakthroughs, especially inhibition of ANP degradation by neprilysin inhibitors. Although ANP is administered intravenously for acute HF, a novel therapeutic strategy is its chronic delivery by subcutaneous injection. An innovative therapeutic development is engineering to develop ANP-based peptides for chronic use. These interconnected topics of ANP biology and therapeutics will be reviewed in detail.",
keywords = "Atrial natriuretic peptide, Cardiorenal biology, cGMP",
author = "Tomoko Ichiki and Burnett, {John C Jr.}",
year = "2017",
doi = "10.1253/circj.CJ-17-0499",
language = "English (US)",
volume = "81",
pages = "913--919",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "7",

}

TY - JOUR

T1 - Atrial natriuretic peptide

T2 - Old but new therapeutic in cardiovascular diseases

AU - Ichiki, Tomoko

AU - Burnett, John C Jr.

PY - 2017

Y1 - 2017

N2 - With the discovery of atrial natriuretic peptide (ANP), the heart as an endocrine organ was established. Basic science revealed that ANP, through the particulate guanylyl cyclase A receptor and cGMP, plays a fundamental role in cardiorenal biology. This work has led to the development of ANP as a therapeutic, especially in heart failure (HF). Human genomics has strengthened our understanding of ANP, revealing specific ANP gene variants that may be associated with biological dysfunction, but also may mediate protective properties, including in metabolic syndrome. Advances in understanding the processing and degradation of ANP molecular forms have resulted in therapeutic breakthroughs, especially inhibition of ANP degradation by neprilysin inhibitors. Although ANP is administered intravenously for acute HF, a novel therapeutic strategy is its chronic delivery by subcutaneous injection. An innovative therapeutic development is engineering to develop ANP-based peptides for chronic use. These interconnected topics of ANP biology and therapeutics will be reviewed in detail.

AB - With the discovery of atrial natriuretic peptide (ANP), the heart as an endocrine organ was established. Basic science revealed that ANP, through the particulate guanylyl cyclase A receptor and cGMP, plays a fundamental role in cardiorenal biology. This work has led to the development of ANP as a therapeutic, especially in heart failure (HF). Human genomics has strengthened our understanding of ANP, revealing specific ANP gene variants that may be associated with biological dysfunction, but also may mediate protective properties, including in metabolic syndrome. Advances in understanding the processing and degradation of ANP molecular forms have resulted in therapeutic breakthroughs, especially inhibition of ANP degradation by neprilysin inhibitors. Although ANP is administered intravenously for acute HF, a novel therapeutic strategy is its chronic delivery by subcutaneous injection. An innovative therapeutic development is engineering to develop ANP-based peptides for chronic use. These interconnected topics of ANP biology and therapeutics will be reviewed in detail.

KW - Atrial natriuretic peptide

KW - Cardiorenal biology

KW - cGMP

UR - http://www.scopus.com/inward/record.url?scp=85021400135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021400135&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-17-0499

DO - 10.1253/circj.CJ-17-0499

M3 - Review article

C2 - 28552863

AN - SCOPUS:85021400135

VL - 81

SP - 913

EP - 919

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 7

ER -